NasdaqGS:REGNBiotechs
Regeneron (REGN) Is Up 5.8% After Positive Phase 2 and 3 Data Across Key Clinical Programs
In early November 2025, Regeneron Pharmaceuticals announced positive Phase 2 trial results for two investigational factor XI antibodies in preventing blood clots during knee surgery, alongside the presentation of favorable Phase 3 data for Dupixent in allergic fungal rhinosinusitis through its collaboration with Sanofi.
These results highlight Regeneron's continued progress in late-stage clinical programs, with multiple new therapeutic indications potentially expanding its addressable...